Press Releases

08-08-2022	Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
08-02-2022	Pliant Therapeutics to Participate in BTIG Biotechnology Conference
07-21-2022	Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis
07-15-2022	Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
07-12-2022	Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering
07-11-2022	Pliant Therapeutics Announces Proposed Public Offering of Common Stock
07-10-2022	Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
06-24-2022	Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial
06-22-2022	Pliant Therapeutics Presents Preclinical Data Highlighting a Novel Approach for the Treatment of Muscular Dystrophies
06-16-2022	Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

Investors & Media